Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Best Peptides to Get to 10% Body Fat Ranked: Effectiveness Comparison

Before selecting a peptide, understand that mechanism must match metabolic state. The table below ranks peptides by body fat range and primary mechanism. Semaglutide (GLP-1) Appetite suppression, delayed gastric emptying 20–15% 0.8–1.2% body weight Moderate (r

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Before selecting a peptide, understand that mechanism must match metabolic state. The table below ranks peptides by body fat range and primary mechanism.
  • Semaglutide (GLP-1)
  • Appetite suppression, delayed gastric emptying
  • 20–15%
  • 0.8–1.2% body weight
  • Moderate (requires high protein intake)
  • Most effective in early deficit phases when hunger is the primary barrier. Loses efficacy below 12% body fat
  • Tirzepatide (GLP-1/GIP dual agonist)
  • Appetite suppression + improved insulin sensitivity
  • 20–14%
  • 1.0–1.4% body weight
  • Moderate to high (better than semaglutide)
  • Strongest overall for initial body recomposition. Dual receptor action maintains effectiveness slightly longer than single GLP-1 agonists
  • CJC-1295/Ipamorelin
  • Growth hormone pulsatile release, IGF-1 elevation
  • 15–8%
  • 0.3–0.6% body weight
  • Very high (primary benefit)
  • Not a direct fat loss agent. Prevents muscle catabolism during aggressive deficits, essential below 12% body fat
  • MK-677 (Ibutamoren)
  • Sustained GH and IGF-1 elevation
  • 0.2–0.5% body weight
  • Very high
  • Oral alternative to injectable secretagogues. Causes water retention in 40–60% of users, which can mask fat loss visually
  • Tesofensine
  • Monoamine reuptake inhibition (thermogenic + appetite suppression)
  • 12–8%
  • 0.5–0.9% body weight
  • Moderate
  • Works when GLP-1 agonists plateau. Increases resting metabolic rate independent of thyroid status
  • Survodutide (GLP-1/Glucagon dual agonist)
  • Appetite suppression + hepatic fat oxidation
  • 18–10%
  • 0.9–1.3% body weight (Phase 3 data)
  • High
  • Combines GLP-1 appetite control with glucagon-driven fatty acid oxidation. Potentially extends efficacy into lower body fat ranges

Related resources

More comparisons